公开(公告)号：US20170073354A1

公开(公告)日：2017-03-16

申请号：US15124635

申请日：2015-03-06

Applicant: Jurgen SCHULZ ,  Peter D. WILLIAMS ,  John A. MCCAULEY ,  Christopher J. BUNGARD ,  David Jonathan BENNETT ,  Sherman T. WADDELL ,  Gregori J. MORRIELLO ,  Lehua CHANG ,  Michael P. DWYER ,  Katharine M. HOLLOWAY ,  Alejandro CRESPO ,  Xin-Jie CHU ,  Catherine WISCOUNT ,  Marie H. LOUGHRAN ,  Jesse J. MANIKOWSKI ,  Kartik M. KEERTIKAR ,  Bin HU ,  Bin ZHONG ,  Tao JI ,  Merck Sharp & Dohme Corp. ,  MSD R&D (China) Co., Ltd.

Inventor： Peter D. Williams ,  John A. McCauley ,  Christopher J. Bungard ,  David Jonathan Bennett ,  Sherman T. Waddell ,  Gregori J. Morriello ,  Lehua Chang ,  Michael P. Dwyer ,  M. Katharine Holloway ,  Alejandro Crespo ,  Xin-Jie Chu ,  Catherine Wiscount ,  H. Marie Loughran ,  Jesse J. Manikowski ,  Jurgen Schulz ,  Kartik M. Keertikar ,  Bin Hu ,  Bin Zhong ,  Tao Ji

IPC: C07D513/08 ,  A61K31/554 ,  A61K45/06

CPC classification number: C07D513/08 ,  A61K31/554 ,  A61K45/06

Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

Abstract translation: 本发明涉及含有该化合物的式I药物组合物的化合物及其在抑制HIV蛋白酶，抑制HIV复制，预防HIV感染，HIV感染治疗和预防， 治疗和延迟艾滋病的发病或进展。

公开(公告)号：US20070093496A1

公开(公告)日：2007-04-26

申请号：US10576328

申请日：2004-10-18

Applicant: John Wai ,  Thorsten Fisher ,  Linghang Zhuang ,  Donnette Staas ,  Terry Lyle ,  Boyoung Kim ,  Mark Embrey ,  Catherine Wiscount ,  Lekhanh Tran ,  Melissa Egbertson ,  Kelly Savage

Inventor： John Wai ,  Thorsten Fisher ,  Linghang Zhuang ,  Donnette Staas ,  Terry Lyle ,  Boyoung Kim ,  Mark Embrey ,  Catherine Wiscount ,  Lekhanh Tran ,  Melissa Egbertson ,  Kelly Savage

IPC: A61K31/498 ,  C07D487/14

CPC classification number: C07D471/14

Abstract: Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract translation: 羟基取代的吡啶并吡咯并吡嗪二酮化合物是HIV整合酶和HIV复制抑制剂的抑制剂。 在一个实施方案中，二酮化合物具有式（I）：（I）其中a，b，A，B，R 1，R 2， R 4，R 4，R 5，R 6，R 7和R 9， 这里定义了8。 这些化合物可用于预防和治疗艾滋病毒感染以及预防，延迟艾滋病的发病和治疗。 这些化合物用作抗感染和艾滋病作为化合物本身或以药学上可接受的盐的形式。 化合物及其盐可以用作药物组合物中的成分，任选与其它抗病毒剂，免疫调节剂，抗生素或疫苗组合使用。